DOP66: The effect of exclusive enteral nutrition on circulating inflammatory protein levels in paediatric patients with Crohn’s DiseaseECCO'21 VirtualYear: 2021
Authors: Pidoux , M.(1);Logan , M.(1);Milling , S.(2);Ijaz , U.Z.(3);Hansen , R.(4);Russell , R.K.(5);Gerasimidis , K.(1)
(1)University of Glasgow, Department of Human Nutrition, Glasgow, United Kingdom;(2)University of Glasgow, Institute for Infection- Immunity and Inflammation, Glasgow, United Kingdom;(3)University of Glasgow, Civil Engineering- School of Engineering, Glasgow, United Kingdom;(4)Royal Hospital for Children, Department of Paediatric Gastroenterology- Hepatology and Nutrition, Glasgow, United Kingdom;(5)Royal Hospital for Sick Children, Department of Paediatric Gastroenterology- Hepatology and Nutrition, Edinburgh, United Kingdom BINGO Group
DOP67: Comparison of the pharmacokinetics of CT-P13 between Crohn’s Disease and Ulcerative Colitis in biologic-naïve patients; a prospective multi-center observational study of the KASIDECCO'21 VirtualYear: 2021
Authors: Kim, E.S.(1);Park, D.I.(2);Kim, H.J.(3);Lee, Y.J.(4);Koo, J.S.(5);Kim, E.S.(6);Yoon, H.(7);Lee, J.H.(8);Kim, J.W.(9);Shin, S.J.(10);Kim, H.W.(11);Kim, H.S.(12);Park, Y.S.(13);Kim, Y.S.(14);Kim, T.O.(15);Lee, J.(16);Choi, C.H.(17);Han, D.S.(18);Chun, J.(19);Kim, H.S.(20)
(1)Kyungpook National University Hospital, Department of Internal Medicine, Daegu, Korea- Republic Of;(2)Sungkyunkwan University School Of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(3)Kyunghee University School Of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(4)Keimyung University School Of Medicine, Internal Medicine, Daegu, Korea- Republic Of;(5)Korea University College Of Medicine, Internal Medicine, Ansan, Korea- Republic Of;(6)Korea University College Of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(7)Seoul National University College Of Medicine, Internal Medicine, Bundang, Korea- Republic Of;(8)Seoul Song Do Colorectal Hospital, Digestive Endoscopic Center, Seoul, Korea- Republic Of;(9)Seoul National University College Of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(10)Ajou University School Of Medicine, Internal Medicine, Suwon, Korea- Republic Of;(11)Pusan National University School Of Medicine And Medical Research Institute, Internal Medicine, Busan, Korea- Republic Of;(12)Yonsei University Wonju College Of Medicine, Internal Medicine, Wonju, Korea- Republic Of;(13)Eulji University School Of Medicine- Eulji Hospital, Internal Medicine, Seoul, Korea- Republic Of;(14)Inje University College Of Medicine- Seoul Paik Hospital, Internal Medicine, Seoul, Korea- Republic Of;(15)Haeundae Paik Hospital- Inje University College Of Medicine, Internal Medicine, Busan, Korea- Republic Of;(16)Chosun University- School Of Medicine, Internal Medicine, Gwangju, Korea- Republic Of;(17)College Of Medicine- Chung-Ang University, Internal Medicine, Seoul, Korea- Republic Of;(18)Hanyang University College Of Medicine, Internal Medicine, Guri, Korea- Republic Of;(19)Gangnam Severance Hospital- Yonsei University College Of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(20)Chonnam University Medical School, Internal Medicine, Gwangju, Korea- Republic Of; The IBD Research Group of the Korean Association for the Study of Intestinal Diseases
DOP68: Assessment of patients' understanding of Inflammatory Bowel Diseases (IBD): Development and validation of a questionnaire (U-IBDQ)ECCO'21 VirtualYear: 2021
Authors: Ostromohov, G.(1);Fiebelman, M.(1,2);Hirsch, A.(1,3);Ron, Y.(1,3);Aviv Cohen , N.(1,3);Kariv , R.(1,3);Deutsch, L.(1,3);Anbar, R.(1,4);Maharshak, N.(3,5);Fliss Isakov, N.(1,6)
(1)Tel Aviv University, Sackler faculty of medicine, Tel Aviv, Israel;(2)Tel Aviv Medical Center, Department of internal medicine, Tel Aviv, Israel;(3)Tel Aviv Medical Center, IBD Center- Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel;(4)Tel Aviv Medical Center, Nutrition and dietetics department at Tel Aviv Medical center, Tel Aviv, Israel;(5)Tel Aviv University, Tel Aviv, Israel;(6)Tel Aviv Sourasky Medical Center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel
DOP69: Ozanimod for induction treatment of Moderate-to-Severe Ulcerative Colitis: Results from a systematic literature review and network meta-analysesECCO'21 VirtualYear: 2021
Authors: Eaton, K.(1);Duperrouzel, C.(1);Bhandari, P.(1);Craigie, S.(1);Bonner, A.(1);Cameron, C.(2);Tencer, T.(3);Kumar, J.(3)
(1)CRG-EVERSANA, Value & Evidence Division- Marketing and Market Access, Ontario, Canada;(2)CRG-EVERSANA, Value & Evidence Division- Marketing and Market Access, Sydney- Nova Scotia, Canada;(3)Bristol Myers Squibb, Global HEOR, Princeton, United States
DOP71: Fungal and bacterial gut microbiota in paediatric onset Inflammatory Bowel Disease introduced to infliximabECCO'21 VirtualYear: 2021
Authors: Ventin-Holmberg, R.(1);Höyhtyä, M.(2);Saqib, S.(3);Korpela, K.(3);Nikkonen, A.(4);Salonen, A.(3);de Vos, W.M.(5);Kolho, K.L.(6)
(1)University of Helsinki, Translational Immunology Research Program, Helsinki, Finland;(2)Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland;(3)University of Helsinki, Human Microbiome Research Program, Helsinki, Finland;(4)Helsinki University Hospital, University of Helsinki and Children´s Hospital, Helsinki, Finland;(5)University of Helsinki- Wageningen University, Human Microbiome Research Program- Laboratory of Microbiology, Helsinki, Finland;(6)University of Helsinki- Helsinki University Hospital, Translational Immunology Research Program- Human Microbiome Research Program- University of Helsinki and Children´s Hospital, Helsinki, Finland
DOP72: Perianal Crohn’s Disease in the biologic era: A population-based cohort studyECCO'21 VirtualYear: 2021
Authors: Jenkinson, P.(1);Plevris, N.(1);Lyons, M.(1);Siakavellas, S.(1);Arnott, I.(1);Jones, G.R.(1);Watson, A.(2);Lees, C.(1)
(1)Edinburgh IBD Unit, Edinburgh IBD Unit, Edinburgh, United Kingdom;(2)Raigmore Hospital, Colorectal Surgery, Inverness, United Kingdom;
DOP73: Antibiotic use differentially affects the risk of antidrug antibody formation during anti-TNFα therapy in Inflammatory Bowel DiseaseECCO'21 VirtualYear: 2021
Authors: Gorelik, Y.(1);Freilich, S.(2);Gerassy-Vainberg, S.(1);Blatt, A.(1);Pressman, S.(1);Focht, G.(3);Friss, C.(3);Loewenberg Weisband, Y.(4);Greenfeld, S.(5);Kariv, R.(5);Ledderman, N.(6);Iris, D.(7);Kashi, Y.(8);Turner, D.(3);Chowers, Y.(1)
(1)Rambam Health Care Campus, Gatroenterology, Haifa, Israel;(2)Rambam Health Care Campus, Gastroenterology, Haifa, Israel;(3)Shaare Zedek Medical Center, Paediatric Gastroenterology, Jerusalem, Israel;(4)Clalit Health Services, Clalit Research Institute- Chief’s Office, Tel Aviv, Israel;(5)Maccabi Healthcare Services, Medical Informatics, Tel Aviv, Israel;(6)Meuhedet Health Services- Tel Aviv- Israel, Medical Manager, Tel Aviv, Israel;(7)Rabin Medical Center, Gastroenterology, Petah Tikva, Israel;(8)Technion Israel Institute of Technology, Faculty of Biotechnology and Food Engineering, Haifa, Israel The Israeli IBD Research Nucleus (IIRN)
DOP74: Initial Clearance of infliximab is a predictor for the time of formation of anti-drug antibodiesECCO'21 VirtualYear: 2021
Authors: Kutschera, M.(1);Primas, C.(1);Reinisch, S.(1);Novacek, G.(1);Kim, S.H.(2);Lee, S.H.(2);Lee , J.H.(2);Reinisch, W.(1);Mould, D.R.(3)
(1)Medical University of Vienna, Department of Gastroenterology and Hepatology, Vienna, Austria;(2)CELLTRION, Inc, Incheon, Korea- Republic Of;(3)Projections Research, Projections Research, Phoenixville, United States
DOP75: Loss-of-response and immunogenicity following immunomodulator withdrawal from anti-tumour necrosis factor alpha combination therapy: Results from a large retrospective cohort studyECCO'21 VirtualYear: 2021
Authors: Mahmoud, R.(1);Schultheiss, J.(1);Louwers, J.(1);van der Kaaij, M.(1);van Hellemondt, B.(1);Mahmmod, N.(2);van Boeckel, P.(2);Jharap, B.(3);Fidder, H.(1);Oldenburg, B.(1)
(1)University Medical Centre Utrecht, Division of Internal Medicine and Dermatology- Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(2)St. Antonius Hospital, Division of Internal Medicine- Department of Gastroenterology and Hepatology, Nieuwegein, The Netherlands;(3)Meander Medical Center, Division of Internal Medicine- Department of Gastroenterology and Hepatology, Amersfoort, The Netherlands
DOP76: No durable impact of COVID-19 on disease activity and microbiome composition in patients with IBDECCO'21 VirtualYear: 2021
Authors: Funez-dePagnier, G.(1);Lima, S.(1);Duenas-Bianchi, L.(1);Lai, D.(1);Ahmed, W.(1);Battat, R.(1);Scherl, E.(1);Lukin, D.(1);Longman, R.(1)
(1)Weill Cornell Medicine, Medicine, New York, United States
DOP77: Effect of Inflammatory Bowel Disease and Related Medications on COVID-19 Incidence, Disease Severity, and Outcome -The Israeli ExperienceECCO'21 VirtualYear: 2021
Authors: Richter, V.(1);Bermont, A.(1);Cohen, D.L.(1);Broide, E.(1);Shirin, H.(1)
(1)Shamir Medical Center, Gastroenterology, Tzerifin, Israel
DOP78: The differential diagnosis and clinicopathological spectrum of Inflammatory Bowel Disease: An interesting and informative ECCO topical reviewECCO'21 VirtualYear: 2021
Authors: Feakins , R.M.(1); Torres, J.(2); Borralho-Nunes, P.(3,4); Burisch, J.(5); Cúrdia Gonçalves, T.(6,7,8); De Ridder, L.(9); Driessen, A.(10); Lobatón, T.(11); Menchén, L.(12,13,14); Mookhoek, A.(15); Noor, N.(16); Svrcek, M.(17); Villanacci, V.(18); Zidar, N.(19); Tripathi, M.(20)
(1)Department of Cellular Pathology, Royal Free London NHS Trust, London, United Kingdom;(2)Department of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal;(3)Department of Pathology, Hospital Cuf Descobertas, Lisbon, Portugal;(4)Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal;(5)Gastrounit, medical division, Hvidovre Hospital, University of Copenhagen, Denmark;(6)Department of Gastroenterology, Hospital da Senhora da Oliveira, Guimarães, Portugal;(7)School of Medicine, University of Minho, Braga/Guimarães, Portugal;(8) ICVS/3B’s–PT Government Associate Laboratory, Braga/Guimarães, Portugal;(9)Department of Paediatric Gastroenterology, Erasmus MC Sophia Children’s Hospital, University Medical Center Rotterdam, The Netherlands;(10)Department of Pathology, University Hospital Antwerp, University Antwerp, Edegem, Belgium;(11)Department of Gastroenterology, Ghent University Hospital, Ghent, Belgium;(12)Department of Digestive System Medicine, Hospital General Universitario-Insitituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain;(13)Department of Medicine, Universidad Complutense, Madrid, Spain;(14)Centro de Investigación Biomédica En Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain;(15)Department of Pathology, Amsterdam UMC, Amsterdam, The Netherlands;(16)Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom;(17)Department of Pathology, Sorbonne Université, AP-HP, Saint-Antoine hospital, Paris, France;(18)Departments of Histopathology, Spedali Civili and University of Brescia, Brescia, Italy;(19)Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia;(20)Department of Histopathology, Cambridge Biomedical Campus, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; TR Clinicopathological spectrum and differential diagnosis of IBD
DOP79: Primary hypogammaglobulinemia with IBD-like features: An ECCO CONFER Multicenter Case SeriesECCO'21 VirtualYear: 2021
Authors: Albshesh, A.(1);Eder, P.(2);Ribaldone , D.G.(3);Oldenburg, B.(4);De Boer, N.K.(5);Mantzaris, G.J.(6); Savarino, E.V.(7);Dragoni , G.(8);Weisshof, R.(9);Truyens, M.(10);Festa, S.(11);Maillard, M.H.(12);Capirchio , L.(13);Filip, R.(14);Kopylov, U.(1)
(1)Sheba Medical Center and Sackler School of Medicine- Tel-Aviv University, Department of Gastroenterology, Tel Aviv, Israel;(2)Heliodor Święcicki University Hospital, Department of Gastroenterology- Dietetics and Internal Medicine- Poznań University of Medical Sciences, Poznań, Poland;(3)University of Turin, Department of Medical Sciences- Division of Gastroenterology, Turin, Italy;(4)University Medical Center Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands Antilles;(5)Amsterdam UMC, Department of Gastroenterology and Hepatology- Vrije Universiteit Amsterdam- Amsterdam Gastroenterology Endocrinology Metabolism Research Insitute AGEM, Amsterdam, Netherlands Antilles;(6)Evangelismos General Hospital of Athens, Department of Gastroenterology, Athen, Greece;(7)University of Padua, Division of Gastroenterology- Department of Surgery- Oncology and Gastroenterology, Padua, Italy;(8)Careggi University Hospital, IBD Referral Center- Department of Gastroenterology, Florence, Italy;(9)Rambam Health Care Campus, Department of Gastroenterology-, Haifa, Israel;(10)Ghent University Hospital, Department of Gastroenterology, Ghent, Belgium;(11)San Filippo Neri Hospital, IBD Unit- Gastroenterology Division, Rome, Italy;(12)Lausanne University Hospital- Crohn and Colitis Center- Gastroentérologie Beaulieu SA, Division of Gastroenterology and Hepatology, Lausanne, Swaziland;(13)Université Catholique de Louvain- Centre Hospitalier Universitaire Université Catholique de Louvain Namur, Department of Gastroenterology, Yvoir, Belgium;(14)Faculty of Medicine- University of Rzeszow, Department of Gastroenterology with IBD Unit of Clinical Hospital No 2 im. Św. Jadwigi Królowej, Rzeszow, Poland
DOP80: Automatic detection of ulcers and erosions in PillCam™ Crohn’s capsule using a convolutional neural networkECCO'21 VirtualYear: 2021
Authors: SaraivaJr., M.(1);Ribeiro, T.(1);Afonso, J.(1);Cardoso, H.(1);Ferreira, J.(2);Andrade, P.(1);Parente, M.(2);Jorge, R.(2);Lopes, S.(1);Macedo, G.(1)
(1)Centro Hospitalar Universitário de S. João- EPE, Gastroenterology, Porto, Portugal;(2)Faculdade de Engenharia da Universidade do Porto, Mechanical Engineering, Porto, Portugal
DOP81: Quality improvement by semi-automated benchmarking of a core outcome quality indicator set in Inflammatory Bowel Disease: A multicentric feasibility studyECCO'21 VirtualYear: 2021
Authors: Bossuyt, P.(1);Baert, D.(2);Baert, F.(3);Hoefkens, E.(1);Huys, I.(2);Lembrechts, N.(1);De Jonckere, E.(3);Dewint, P.(2);Pouillon, L.(1)
(1)Imelda General Hospital Bonheiden, Department of Gastroenterology, Bonheiden, Belgium;(2)AZ Maria Middelares, Gastroenterology, Gent, Belgium;(3)AZ Delta, Gastroenterology, Rumbeke, Belgium
DOP82: Corticosteroid-free remission of Ulcerative Colitis with filgotinib maintenance therapy: Post hoc analysis of the phase 2b/3 SELECTION studyECCO'21 VirtualYear: 2021
Authors: Loftus- Jr, E.(1);Vermeire, S.(2);Feagan, B.(3);Yun, C.(4);Hsieh, J.(4);Liu, X.(4);Zhao, S.(4);Moerch, U.(5);Sandborn, W.J.(6);Hibi, T.(7)
(1)Mayo Clinic, Department of Internal Medicine- Department of Gastroenterology and Hepatology, Rochester- MN, United States;(2)University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium;(3)Western University, Department of Medicine- Division of Gastroenterology, London- ON, Canada;(4)Gilead Sciences, Inc., Foster City, United States;(5)Gilead Sciences, Inc., Copenhagen, Denmark;(6)University of California, Department of Medicine, San Diego- La Jolla- CA, United States;(7)Kitasato Institute Hospital- Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan
DOP83: Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term ExtensionECCO'21 VirtualYear: 2021
Authors: Abreu, M.T.(1);Danese, S.(2);Sandborn, W.J.(3);Miao, Y.(4);Tikhonov, I.(4);Zhang, H.(4);Panaccione, R.(5);Hisamatsu, T.(6);Scherl, E.J.(7);Leong, R.W.(8);Rowbotham, D.S.(9);Arasaradnam, R.P.(10);Afif, W.(11);Peyrin-Biroulet, L.(12);Sands, B.E.(13);Marano, C.(4)
(1)University of Miami Miller School of Medicine, Department of Medicine, Miami, United States;(2)Istituto Clinico Humanitas, Department of Gastroenterology, Milano, Italy;(3)University of California San Diego, Division of Gastroenterology, San Diego, United States;(4)Janssen Research & Development- LLC., Immunology, Spring House, United States;(5)University of Calgary, Inflammatory Bowel Disease Unit, Calgary, Canada;(6)Kyorin University School of Medicine, Third Department of Internal Medicine, Tokyo, Japan;(7)New York Presbyterian Weill Cornell Medical College, Roberts Center for Inflammatory Bowel Disease, New York, United States;(8)Concord Repatriation General Hospital, Inflammatory Bowel Disease Clinic, Concord, Australia;(9)Auckland City Hospital, Gastroenterology, Auckland, New Zealand;(10)University Hospital Coventry & Warwickshire, GI Medicine, Coventry, United Kingdom;(11)McGill University Health Center, Division of Gastroenterology, Montreal, Canada;(12)Nancy University Hospital- Université de Lorraine, Department of Gastroenterology, Nancy, France;(13)Mount Sinai School of Medicine, Henry D. Janowitz Division of Gastroenterology, New York, United States
DOP84: Early treatment responses within 14 days of intravenous vedolizumab induction therapy for Crohn’s Disease: Post hoc analysis of patient-reported outcomes from the VISIBLE 2 studyECCO'21 VirtualYear: 2021
Authors: D'Haens, G.(1);Baert, F.(2);Danese, S.(3);Kobayashi, T.(4);Loftus Jr., E.V.(5);Sandborn, W.J.(6);Dornic, Q.(7);Lindner, D.(7);Kisfalvi, K.(8);Marins, E.G.(8);Vermeire, S.(9)
(1)Amsterdam University Medical Centers, Department of Gastroenterology, Amsterdam, The Netherlands;(2)AZ Delta, Department of Gastroenterology, Roeselare, Belgium;(3)Humanitas University, Department of Gastroenterology, Milan, Italy;(4)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(5)Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Rochester, United States;(6)University of California San Diego, Department of Medicine, San Diego, United States;(7)Takeda, Statistical and Quantitative Science, Zurich, Switzerland;(8)Takeda, Global Medical Affairs, Cambridge, United States;(9)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium
DOP85: Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance studyECCO'21 VirtualYear: 2021
Authors: Vavricka, S.R.(1);Greuter, T.(2);Cohen, B.L.(3);Reinisch, W.(4);Steinwurz, F.(5);Fellmann, M.(6);Guo, X.(7);Lawendy, N.(7);Paulissen, J.(8);Peyrin-Biroulet, L.(9)
(1)Department of Gastroenterology and Hepatology- University Hospital Zurich, and Center for Gastroenterology and Hepatology, Zürich, Switzerland;(2)Department of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland;(3)Department of Gastroenterology- Hepatology- and Nutrition, Digestive Disease and Surgery Institute- Cleveland Clinic, Cleveland- Ohio, United States;(4)-, Medical University of Vienna, Vienna, Austria;(5)Unit of Inflammatory Bowel Disease, Hospital Israelita Albert Einstein, São Paulo, Brazil;(6)Pfizer Switzerland AG, Zürich, Switzerland;(7)Pfizer Inc, Collegeville, Pennsylvania, United States;(8)Pfizer Inc, New York, New York, United States;(9)Department of Gastroenterology, Inserm U1256 NGERE- Nancy University Hospital- Université de Lorraine, Vandœuvre-lès-Nancy, France
